Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus VELOSEF 500.
CECLOR CD vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic